Developer docs
API playgroundTry for free, no card

Search company profiles

SQZ Biotech

Full company profile

uuid0000qfb

Namestring
SQZ Biotech
Legal namestring
SQZ Biotechnologies Company
Websiteurl
sqzbiotech.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

SQZ Biotechnologies Company was a clinical-stage biotechnology company that developed a proprietary cell engineering platform called Cell Squeeze®, which uses microfluidic mechanical compression to deliver diverse materials (proteins, nucleic acids, other cargo) into patient cells without compromising viability. The platform was positioned to reprogram immune cells into specialized cell types — including dopamine-producing neurons — for potential application in Parkinson's disease, Multiple Sclerosis, Type 1 diabetes, and other indications. The company was headquartered in Watertown (with a listed Wayland, MA address), was publicly traded on the NYSE under the ticker SQZ, and employed 51-100 people prior to dissolution.

The business model centered on developing internal therapeutic candidates and partnering with academic and government funders such as the NIH (which awarded a $2 million SBIR Phase II grant in 2022 for Parkinson's research). SQZ also pursued biopharma collaborations and had raised over $160 million in cumulative equity and grant financing across multiple rounds from investors including Polaris Partners, GV, Temasek, Illumina Ventures, and JDRF T1D Fund.

On March 4, 2024, SQZ sold substantially all of its assets — including the Cell Squeeze® technology and associated intellectual property — to STEMCELL Technologies Canada Acquisitions, Inc. and filed a Certificate of Dissolution with the Delaware Secretary of State. STEMCELL subsequently launched the CellPore™ Transfection System as the commercial successor to the Cell Squeeze® platform, distributing it through its life-science research tools channels.

Short descriptiontext

SQZ Biotechnologies was a publicly traded (NYSE:SQZ) clinical-stage biotech that developed the Cell Squeeze® microfluidic cell engineering platform for cell therapies in Parkinson's, MS, and Type 1 diabetes. It dissolved on March 4, 2024 after selling its assets to STEMCELL Technologies.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell engineering platform, microfluidic cell delivery, cell therapy development, immunotherapy research, biotechnology therapeutics
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology / Cell Therapy
Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SQZ Biotechnologies developed and commercialized the Cell Squeeze® technology, a microfluidic cell engineering platform that mechanically delivers materials into patient cells without compromising viability. The platform was used to engineer immune cells into specialized cell types, including dopamine-producing neurons, for cell therapy programs targeting Parkinson's disease, Multiple Sclerosis, and Type 1 diabetes. All assets, including intellectual property and the Cell Squeeze® technology, were sold to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SQZ Biotechnologies was a biotechnology company offering the Cell Squeeze® technology, a cell engineering platform that enabled the delivery of materials into cells. The company operated as a single-product-focused organization with its core technology as the primary offering. On March 4, 2024, SQZ Biotechnologies sold substantially all of its assets, including its intellectual property and Cell Squeeze® technology, to STEMCELL Technologies Canada Acquisitions, Inc., and subsequently filed for dissolution. STEMCELL Technologies now offers the CellPore™ Transfection System, described as a successor to the Cell Squeeze technology.

Product and service1 record
1Cell Squeeze® Technology
CategoryCell engineering platform technology
Description

A proprietary cell engineering platform that uses microfluidic squeezing to deliver materials into cells without compromising viability, enabling reprogramming of immune cells into specialized cell types for therapeutic use. It was sold to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024 and is now commercialized as the CellPore™ Transfection System by STEMCELL.

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-03-04
Description

SQZ Biotechnologies sold substantially all of its assets including intellectual property and the Cell Squeeze technology to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024. The company also filed a Certificate of Dissolution with the Secretary of State of Delaware on the same date. STEMCELL Technologies now offers the CellPore Transfection System, which is based on the acquired Cell Squeeze technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SQZ Biotech

Biotechnology / Cell Therapysqzbiotech.com

SQZ Biotechnologies was a publicly traded (NYSE:SQZ) clinical-stage biotech that developed the Cell Squeeze® microfluidic cell engineering platform for cell therapies in Parkinson's, MS, and Type 1 diabetes. It dissolved on March 4, 2024 after selling its assets to STEMCELL Technologies.

What SQZ Biotech does

SQZ Biotechnologies Company was a clinical-stage biotechnology company that developed a proprietary cell engineering platform called Cell Squeeze®, which uses microfluidic mechanical compression to deliver diverse materials (proteins, nucleic acids, other cargo) into patient cells without compromising viability. The platform was positioned to reprogram immune cells into specialized cell types — including dopamine-producing neurons — for potential application in Parkinson's disease, Multiple Sclerosis, Type 1 diabetes, and other indications. The company was headquartered in Watertown (with a listed Wayland, MA address), was publicly traded on the NYSE under the ticker SQZ, and employed 51-100 people prior to dissolution.

The business model centered on developing internal therapeutic candidates and partnering with academic and government funders such as the NIH (which awarded a $2 million SBIR Phase II grant in 2022 for Parkinson's research). SQZ also pursued biopharma collaborations and had raised over $160 million in cumulative equity and grant financing across multiple rounds from investors including Polaris Partners, GV, Temasek, Illumina Ventures, and JDRF T1D Fund.

On March 4, 2024, SQZ sold substantially all of its assets — including the Cell Squeeze® technology and associated intellectual property — to STEMCELL Technologies Canada Acquisitions, Inc. and filed a Certificate of Dissolution with the Delaware Secretary of State. STEMCELL subsequently launched the CellPore™ Transfection System as the commercial successor to the Cell Squeeze® platform, distributing it through its life-science research tools channels.

SQZ Biotech firmographics

Firmographics
Name
SQZ Biotech
Legal name
SQZ Biotechnologies Company
Website
https://sqzbiotech.com
Company type
Public
Founded year
2013
Operating status
Closed
Headcount range
51–100 employees
Short description
SQZ Biotechnologies was a publicly traded (NYSE:SQZ) clinical-stage biotech that developed the Cell Squeeze® microfluidic cell engineering platform for cell therapies in Parkinson's, MS, and Type 1 diabetes. It dissolved on March 4, 2024 after selling its assets to STEMCELL Technologies.
Ownership category
akta.pro rank

SQZ Biotech industry classification

Industry
Product category
Biotechnology / Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell engineering platform
  • Microfluidic cell delivery
  • Cell therapy development
  • Immunotherapy research
  • Biotechnology therapeutics

Where SQZ Biotech is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Markets served

SQZ Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

SQZ Biotech product offering

Product offering

Core offering

SQZ Biotechnologies developed and commercialized the Cell Squeeze® technology, a microfluidic cell engineering platform that mechanically delivers materials into patient cells without compromising viability. The platform was used to engineer immune cells into specialized cell types, including dopamine-producing neurons, for cell therapy programs targeting Parkinson's disease, Multiple Sclerosis, and Type 1 diabetes. All assets, including intellectual property and the Cell Squeeze® technology, were sold to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024.

Product overview

SQZ Biotechnologies was a biotechnology company offering the Cell Squeeze® technology, a cell engineering platform that enabled the delivery of materials into cells. The company operated as a single-product-focused organization with its core technology as the primary offering. On March 4, 2024, SQZ Biotechnologies sold substantially all of its assets, including its intellectual property and Cell Squeeze® technology, to STEMCELL Technologies Canada Acquisitions, Inc., and subsequently filed for dissolution. STEMCELL Technologies now offers the CellPore™ Transfection System, described as a successor to the Cell Squeeze technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell Squeeze® Technology A proprietary cell engineering platform that uses microfluidic squeezing to deliver materials into cells without compromising viability, enabling reprogramming of immune cells into specialized cell types for therapeutic use. It was sold to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024 and is now commercialized as the CellPore™ Transfection System by STEMCELL.

Companies that use SQZ Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

SQZ Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SQZ Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • STEMCELL Technologies Canada Acquisitions, Inc.coreOEM/ Whitelabel/ Licensing Partner · 4 March 2024SQZ Biotechnologies sold substantially all of its assets including intellectual property and the Cell Squeeze technology to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024. The company also filed a Certificate of Dissolution with the Secretary of State of Delaware on the same date. STEMCELL Technologies now offers the CellPore Transfection System, which is based on the acquired Cell Squeeze technology.

Recent moves7 records

SQZ Biotech competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

SQZ Biotech social profiles

Digital presence

SQZ Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SQZ Biotech leadership team

Management profile

Number of profiles

Profiles11 records

SQZ Biotech funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SQZ Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SQZ Biotech

What does SQZ Biotech do?

SQZ Biotechnologies developed and commercialized the Cell Squeeze® technology, a microfluidic cell engineering platform that mechanically delivers materials into patient cells without compromising viability. The platform was used to engineer immune cells into specialized cell types, including dopamine-producing neurons, for cell therapy programs targeting Parkinson's disease, Multiple Sclerosis, and Type 1 diabetes. All assets, including intellectual property and the Cell Squeeze® technology, were sold to STEMCELL Technologies Canada Acquisitions, Inc. on March 4, 2024.

Is SQZ Biotech a public or private company?

SQZ Biotech is a public company. It is classified as public and is currently closed.

When was SQZ Biotech founded?

SQZ Biotech was founded in 2013. It employs 51 to 100 people.

Where is SQZ Biotech based?

SQZ Biotech is headquartered in Watertown, United States, in the North America region.

Does SQZ Biotech have an API?

No public API is recorded for SQZ Biotech.

What industry is SQZ Biotech in?

SQZ Biotech's product category is Biotechnology / Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsSQZ Biotechnologies (SQZB) Projected to Release Quarterly Earnings on ThursdaySQZ Biotechnologies is projected to release its quarterly earnings on Thursday, November 12th. Analysts expect a loss of $0.5825 per share and revenue of $4.66 million. The stock opened at $0.02, with a 12-month range of $0.01 to $0.05.American Banking and Market NewsSQZ Biotechnologies Company (OTCMKTS:SQZB) Sees Large Drop in Short InterestSQZ Biotechnologies saw short interest fall 65.7% in September, from 18,887 shares on Sept. 15 to 6,479 on Sept. 30. The stock opened at $0.02 with a market cap of $707,760, and the company develops cell therapies using its Cell Squeeze platform.Ticker ReportFinancial Comparison: Galectin Therapeutics (NASDAQ:GALT) vs. SQZ Biotechnologies (NYSE:SQZ)A MarketBeat comparison rated Galectin Therapeutics (NASDAQ:GALT) higher than SQZ Biotechnologies (NYSE:SQZ) on 8 of 13 factors, including lower P/E ratio, higher institutional ownership and a consensus target price of $11.00 implying 172.95% upside. SQZ reported $18.16 million revenue and a beta of 2.34, while Galectin's beta was 0.41.Markets DailySQZ Biotechnologies (SQZB) Projected to Post Quarterly Earnings on FridaySQZ Biotechnologies is projected to announce its quarterly earnings on Friday, August 14th, with analysts expecting a loss of $0.5825 per share and revenue of $4.6620 million. The company is a clinical-stage biotechnology firm focusing on developing cell therapies through its proprietary technology. Its pipeline targets several disease areas, including oncology and infectious diseases.Defense WorldFinancial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)This article presents a financial comparison between two NASDAQ-listed clinical-stage biotech companies: SQZ Biotechnologies and Cortexyme. The analysis compares institutional ownership, stock volatility, profitability metrics, and valuation indicators across ten factors. SQZ Biotechnologies outperforms Cortexyme on 6 of the 10 comparison factors, though both companies are unprofitable with significant net losses.American City Business JournalsSQZ Biotechnologies sells assets to Stemcell, Canada’s largest biotechStemcell Technologies acquired substantially all assets of SQZ Biotechnologies for $11.8 million in cash, approved by SQZ shareholders. The deal includes over 400 patents and trademarks, and SQZ had laid off most of its staff in November.Business Wire BlogSQZ Biotechnologies Provides Update on Collaboration with RocheRoche decided not to exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program, so SQZ Biotechnologies regained full clinical development and commercialization rights. The company will explore strategic partnerships to advance its oncology programs, with Phase 1 data anticipated in the second half of 2023.BenzingaShort Volatility Alert: Sqz BiotechnologiesOn Thursday, shares of Sqz Biotechnologies (NYSE:SQZ) experienced volatile short selling activity, with the stock price rising +32.65% to $0.80 following the unusual activity detected on 3/23/2023. The securities lending volatility indicator, produced by Tidal Markets in partnership with Benzinga Insights, detected a volatility change of +92.6% with the current volatility indicator at 14.532. The volatility alert signal is trending Bearish, with a recommendation to Increase Short Exposure.BenzingaSQZ Biotech's Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor PatientSQZ Biotechnologies announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 trial for HPV16+ cancers. The 61-year-old patient with metastatic rectal squamous cell carcinoma showed progressive improvement, achieving partial response after two cycles and complete response after seven cycles of treatment, with no dose-limiting toxicity reported. The Study Safety Committee has recommended advancing to the highest dose cohort, with initial data from that cohort expected in Q4 2023.